New drug combo for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has spread or returned after immunotherapy.
- You are at least 18 years old and can provide a tumor sample from before treatment.
- You have not had gemcitabine combined with immunotherapy before.
- You have stable brain metastases if treated, and no active or serious heart, lung, or bleeding problems.
- You agree to use effective contraception during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain (leptomeningeal metastases) and has stopped responding to standard EGFR-targeted pills. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a combination of platinum chemotherapy, a paclitaxel nanoparticle formulation, and ivonescimab (an immunotherapy) as the first treatment for people with advanced squamous non-small cell lung cancer that has spread or come back. The goal is to see if this combination helps shrink or control the cancer.
This study tests a new drug, ivonescimab, alone or with chemotherapy (carboplatin and pemetrexed), for people with advanced lung cancer that has specific gene changes and has already been treated with targeted therapy. It aims to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.